561 related articles for article (PubMed ID: 16286094)
21. Medicine and science in the fight against doping in sport.
Catlin DH; Fitch KD; Ljungqvist A
J Intern Med; 2008 Aug; 264(2):99-114. PubMed ID: 18702750
[TBL] [Abstract][Full Text] [Related]
22. Strengths and weaknesses of established indirect models to detect recombinant human erythropoietin abuse on blood samples collected 48-hr post administration.
Connes P; Caillaud C; Simar D; Villard S; Sicart MT; Audran M
Haematologica; 2004 Jul; 89(7):891-2. PubMed ID: 15257956
[TBL] [Abstract][Full Text] [Related]
23. Gene doping: an overview and current implications for athletes.
van der Gronde T; de Hon O; Haisma HJ; Pieters T
Br J Sports Med; 2013 Jul; 47(11):670-8. PubMed ID: 23322893
[TBL] [Abstract][Full Text] [Related]
24. Emerging drugs: mechanism of action, mass spectrometry and doping control analysis.
Thevis M; Thomas A; Kohler M; Beuck S; Schänzer W
J Mass Spectrom; 2009 Apr; 44(4):442-60. PubMed ID: 19373874
[TBL] [Abstract][Full Text] [Related]
25. [The fight against doping: today and tomorrow].
Rieu M
Bull Acad Natl Med; 2004; 188(6):955-71; discussion 972. PubMed ID: 15651425
[TBL] [Abstract][Full Text] [Related]
26. Erythropoietin and blood doping.
Robinson N; Giraud S; Saudan C; Baume N; Avois L; Mangin P; Saugy M
Br J Sports Med; 2006 Jul; 40 Suppl 1(Suppl 1):i30-4. PubMed ID: 16799100
[TBL] [Abstract][Full Text] [Related]
27. Detection of recombinant human erythropoietin in urine for doping analysis: interpretation of isoelectric profiles by discriminant analysis.
Lasne F; Thioulouse J; Martin L; de Ceaurriz J
Electrophoresis; 2007 Jun; 28(12):1875-81. PubMed ID: 17503402
[TBL] [Abstract][Full Text] [Related]
28. Gene doping detection: evaluation of approach for direct detection of gene transfer using erythropoietin as a model system.
Baoutina A; Coldham T; Bains GS; Emslie KR
Gene Ther; 2010 Aug; 17(8):1022-32. PubMed ID: 20463760
[TBL] [Abstract][Full Text] [Related]
29. "Genetic Doping" with erythropoietin cDNA in primate muscle is detectable.
Lasne F; Martin L; de Ceaurriz J; Larcher T; Moullier P; Chenuaud P
Mol Ther; 2004 Sep; 10(3):409-10. PubMed ID: 15336641
[No Abstract] [Full Text] [Related]
30. Beyond sports-doping headlines: the science of laboratory tests for performance-enhancing drugs.
Hatton CK
Pediatr Clin North Am; 2007 Aug; 54(4):713-33, xi. PubMed ID: 17723873
[TBL] [Abstract][Full Text] [Related]
31. Growth hormone and the adolescent athlete: What are the data for its safety and efficacy as an ergogenic agent?
Rogol AD
Growth Horm IGF Res; 2009 Aug; 19(4):294-9. PubMed ID: 19487146
[TBL] [Abstract][Full Text] [Related]
32. A global strategy for prevention and detection of blood doping with erythropoietin and related drugs.
Cazzola M
Haematologica; 2000 Jun; 85(6):561-3. PubMed ID: 10870110
[No Abstract] [Full Text] [Related]
33. Developing strategies for detection of gene doping.
Baoutina A; Alexander IE; Rasko JE; Emslie KR
J Gene Med; 2008 Jan; 10(1):3-20. PubMed ID: 18081214
[TBL] [Abstract][Full Text] [Related]
34. Indirect markers for detecting growth hormone abuse by athletes.
Banfi G; Colombini A; Lombardi G
Clin Endocrinol (Oxf); 2010 Aug; 73(2):272-3; author reply 274-5. PubMed ID: 20201950
[No Abstract] [Full Text] [Related]
35. [Oxygen blood transport and doping].
Audran M; Connes P; Varlet-Marie E
Bull Acad Natl Med; 2003; 187(9):1669-79; discussion 1680-3. PubMed ID: 15369237
[TBL] [Abstract][Full Text] [Related]
36. Quantification of human insulin-like growth factor-1 and qualitative detection of its analogues in plasma using liquid chromatography/electrospray ionisation tandem mass spectrometry.
Bredehöft M; Schänzer W; Thevis M
Rapid Commun Mass Spectrom; 2008; 22(4):477-85. PubMed ID: 18236437
[TBL] [Abstract][Full Text] [Related]
37. Gene doping: the hype and the harm.
McKanna TA; Toriello HV
Pediatr Clin North Am; 2010 Jun; 57(3):719-27. PubMed ID: 20538153
[TBL] [Abstract][Full Text] [Related]
38. Erythropoietin doping. A comment.
Remacha AF
Haematologica; 2000; 85(E-letters):E04. PubMed ID: 11114819
[No Abstract] [Full Text] [Related]
39. [Medication, athletes and doping regulations].
Hartgens F
Ned Tijdschr Geneeskd; 2008 Aug; 152(33):1844-8. PubMed ID: 18783164
[TBL] [Abstract][Full Text] [Related]
40. Overview of the legal framework applicable to the marker method for the detection of human growth hormone.
Young RR; Bielak JS; Horvitz SL
Growth Horm IGF Res; 2009 Aug; 19(4):366-8. PubMed ID: 19608446
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
